24.8 C
New York
Saturday, June 6, 2026

Tag: obesity

newssourceFORcompanyinformationcontent1marketreleases

BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

MELVILLE, N.Y., Aug. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its second quarter 2025 financial results after market close on Tuesday, August 12, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update.

The American Diabetes Association Marks 85 Years of Advancements in Diabetes Care and Discovery

ARLINGTON, Va., Aug. 5, 2025 /PRNewswire/ -- This month, the American Diabetes Association® (ADA) celebrates 85 years of dedicated work toward its vision of...

Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance

   
Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance

Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032

SAN FRANCISCO and SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...

Hims & Hers Health, Inc. (HIMS) – Lawmakers Urge Crackdown On Illegal Weight Loss Drugs, Novo’s Termination of Collaboration With HIMS Triggers Securities Class...

HIMS Investors with Losses Encouraged to Contact Hagens Berman 
HIMS Investors with Losses Encouraged to Contact Hagens Berman

Homestyle Direct Expands Access to Medically Tailored Meals in California

Delivering Nutritious Meals Across Five Counties TWIN FALLS, Idaho, Aug. 4, 2025 /PRNewswire/ -- Homestyle Direct is proud to announce its expansion into several new California...

Homestyle Direct Medically Tailored Meal Delivery Scores High in Pennsylvania

Delivering Nutritious Meals for Eligible Medicaid Members in Erie and Allegheny Counties TWIN FALLS, Idaho, Aug. 4, 2025 /PRNewswire/ -- Homestyle Direct is quickly becoming...

Digital Therapeutics Market to Grow at a CAGR of 26.3% from 2025 to 2032 | SkyQuest Technology Consulting

The digital therapeutics market is anticipated to increase due to the growing global burden of chronic conditions such as diabetes, cardiovascular disorders, and obesity...

Digital Therapeutics Market to Grow at a CAGR of 26.3% from 2025 to 2032 | SkyQuest Technology Consulting

The digital therapeutics market is anticipated to increase due to the growing global burden of chronic conditions such as diabetes, cardiovascular disorders, and obesity...

Evidence review suggests COVID-19 vaccines safe for pregnant women and their babies

WILLOW GROVE, Pa., July 31, 2025 /PRNewswire/ -- Pregnant women are at increased risk of illness due to infection compared with other adults, so...

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

CONSHOHOCKEN, Pa., July 30, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal”) today announced that it has entered into an exclusive global license agreement with CSPC Pharmaceutical Group Limited (HKEX Stock CodeL 1093) (“CSPC”) for SYH2086, a preclinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and orforglipron derivative. Madrigal plans to initiate clinical development in the first half of 2026.

LipoVive Releases Ingredient Report Comparing Natural GLP-1 Support to Synthetic Drugs Like Mounjaro

A Plant-Based Formula With Science-Referenced Compounds Designed to Support Hormonal Weight Balance Without Prescription Medications 
A Plant-Based Formula With Science-Referenced Compounds Designed to Support Hormonal Weight Balance Without Prescription Medications

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsObesity

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers